Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy
Charlotte Lee, Zsófia D. Drobni, Amna Zafar, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 660-669
Open Access | Times Cited: 22

Showing 22 citing articles:

Changes in frailty and incident cardiovascular disease in three prospective cohorts
Di He, Zhaoping Wang, Jun Li, et al.
European Heart Journal (2024)
Closed Access | Times Cited: 80
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 15
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
Betul Ibis, Konstantinos Aliazis, Carol Cao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 39
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
Silvia Casagrande, Giulia Boscato Sopetto, Giovanni Bertalot, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1440-1440
Open Access | Times Cited: 14
Cardiovascular Considerations Before Cancer Therapy
Zahra Raisi‐Estabragh, A. Murphy, Sivatharshini Ramalingam, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 5, pp. 631-654
Open Access | Times Cited: 7
Anti‐CTLA‐4 m2a Antibody Exacerbates Cardiac Injury in Experimental Autoimmune Myocarditis Mice By Promoting Ccl5‐Neutrophil Infiltration
Ming‐Ming Wu, Yan‐Chao Yang, Yong‐Xu Cai, et al.
Advanced Science (2024)
Open Access | Times Cited: 6
A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease
María A. López-Olivo, Johncy John Kachira, Noha Abdel‐Wahab, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114148-114148
Closed Access | Times Cited: 5
Underpinnings of Heart Failure With Preserved Ejection Fraction in Women - From Prevention to Improving Function. A Co-publication With the American Journal of Preventive Cardiology and the Journal of Cardiac Failure
Archanna Radakrishnan, Shashank Agrawal, Neha Singh, et al.
Journal of Cardiac Failure (2025)
Closed Access
Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure
Archanna Radakrishnan, Saloni Agrawal, Nausheen Singh, et al.
American Journal of Preventive Cardiology (2025), pp. 100928-100928
Open Access
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Keila C. Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Advances in immune checkpoint inhibitors induced-cardiotoxicity
Xiang Li, Wenying Peng, Jiao Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Impact of baseline glucocorticoids (GCs) on cardiotoxic events and myocardial damage related to immune checkpoint inhibitors: a retrospective clinical research
Qiaoyun Wang, Haixia Zhang, Yawen Chen, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
SITC strategic vision: prevention, premalignant immunity, host and environmental factors
Sasha E. Stanton, Kristin G. Anderson, Tullia C. Bruno, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010419-e010419
Open Access
Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study
Isabel Manger, Cynthia L. Schmitt, Carola Berking, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 3
Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System
Stefan Milutinovic, Predrag Jancic, Vera Jokić, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1372-1372
Open Access | Times Cited: 2
Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database
Alistair C Lindsay, Alexander M. Walker, Sebastian Schneeweiß
Journal of the American Heart Association (2024)
Open Access | Times Cited: 2
Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy
Yuxi Luo, Zhimin Zeng, Yunwei Liu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 189008-189008
Closed Access | Times Cited: 4
Reconciling immunotherapy and autoimmunity: not for the faint of heart
Carrie Ye
The Lancet Rheumatology (2023) Vol. 5, Iss. 5, pp. e243-e245
Closed Access | Times Cited: 2
Multiple sclerosis and cancer: Navigating a dual diagnosis
Cassie Nesbitt, Anneke van der Walt, Helmut Butzkueven, et al.
Multiple Sclerosis Journal (2024)
Closed Access
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective
Stefano Poletto, Luca Paruzzo, Alessandro Nepote, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 101-101
Open Access | Times Cited: 1
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?
Paaladinesh Thavendiranathan, Adrian G. Sacher
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 670-672
Open Access | Times Cited: 2
Page 1

Scroll to top